What is he best known for?
The fields of study he is best known for:
- Cancer
- Immune system
- Antibody
The scientist’s investigation covers issues in Antigen, Immunology, Antibody, Immune system and CD8.
His studies in Antigen integrate themes in fields like T cell, Cytotoxic T cell and Immunotherapy, NY-ESO-1.
Immunology is frequently linked to Cancer in his study.
His Cancer study incorporates themes from BCG vaccine and Oncology.
His Antibody study frequently draws connections to other fields, such as Molecular biology.
His IL-2 receptor study integrates concerns from other disciplines, such as Survival rate, Tumor-infiltrating lymphocytes and FOXP3.
His most cited work include:
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer (1739 citations)
- Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. (474 citations)
- NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. (421 citations)
What are the main themes of his work throughout his whole career to date?
Gerd Ritter focuses on Antigen, Immunology, Antibody, Immune system and Molecular biology.
The concepts of his Antigen study are interwoven with issues in Cytotoxic T cell, Immunotherapy, NY-ESO-1 and T cell.
Gerd Ritter has researched Immunology in several fields, including Cancer and Cancer research.
His Cancer research incorporates elements of Clinical trial, Melanoma and Oncology.
His work on Monoclonal antibody, Immunogenicity and Humanized antibody as part of general Antibody study is frequently linked to Antibody titer, bridging the gap between disciplines.
His Molecular biology research includes themes of Monoclonal Antibody A33 and Polyclonal antibodies.
He most often published in these fields:
- Antigen (59.64%)
- Immunology (48.80%)
- Antibody (45.18%)
What were the highlights of his more recent work (between 2010-2019)?
- Immunology (48.80%)
- Antigen (59.64%)
- Antibody (45.18%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Immunology, Antigen, Antibody, Cancer and Immune system.
His Immunology study frequently links to adjacent areas such as Virology.
The Antigen study combines topics in areas such as Antigen-presenting cell, T cell, Tumor antigen, Cytotoxic T cell and Antigen presentation.
His work in the fields of Antibody, such as Monoclonal antibody, Immunogenicity and Epitope, overlaps with other areas such as Antibody titer.
His Cancer study incorporates themes from Translational research, Clinical trial, Phases of clinical research, Receptor and Melanoma.
His work on Cancer/testis antigens as part of his general Immune system study is frequently connected to Population, thereby bridging the divide between different branches of science.
Between 2010 and 2019, his most popular works were:
- Colon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues (190 citations)
- Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients (183 citations)
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients (138 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Immune system
- Antibody
His main research concerns Immunology, Antigen, Antibody, Cancer and Internal medicine.
In the subject of general Immunology, his work in Cancer immunotherapy is often linked to Public relations, thereby combining diverse domains of study.
His research in Antigen intersects with topics in T cell, IL-2 receptor, Immune system, Antigen-presenting cell and NY-ESO-1.
Within one scientific family, Gerd Ritter focuses on topics pertaining to Adjuvant under Antibody, and may sometimes address concerns connected to Prostate cancer.
Gerd Ritter combines subjects such as Translational research and Clinical trial with his study of Cancer.
His biological study spans a wide range of topics, including Oncology and Biodistribution.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
